Literature DB >> 21927980

CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.

C M Wang, H Fu, G F Zhao, J Wang, Y Q Shi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21927980     DOI： 10.1007/s12253-011-9445-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


× No keyword cloud information.
  8 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI.

Authors:  Christian Stroszczynski; Dominik Jost; Peter Reichardt; Petra Chmelik; Gunnar Gaffke; Albrecht Kretzschmar; Ulrike Schneider; Roland Felix; Peter Hohenberger
Journal:  Eur Radiol       Date:  2005-08-13       Impact factor: 5.315

3.  We should desist using RECIST, at least in GIST.

Authors:  Robert S Benjamin; Haesun Choi; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Chuslip Charnsangavej
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

4.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

5.  Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET.

Authors:  Pieter L Jager; Jourik A Gietema; Winette T A van der Graaf
Journal:  Nucl Med Commun       Date:  2004-05       Impact factor: 1.690

6.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

7.  Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate.

Authors:  Sith Phongkitkarun; Cholada Phaisanphrukkun; Janjira Jatchavala; Ekaphop Sirachainan
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

8.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana de Castro Faria; Eric P Tamm; Robert S Benjamin; Marcella M Johnson; Homer A Macapinlac; Donald A Podoloff
Journal:  AJR Am J Roentgenol       Date:  2004-12       Impact factor: 3.959
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.